Phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment for HER-2-positive locally recurrent or metastatic breast cancer

  1. Martín, M.
  2. Makhson, A.
  3. Gligorov, J.
  4. Lichinitser, M.
  5. Lluch, A.
  6. Semiglazov, V.
  7. Scotto, N.
  8. Mitchell, L.
  9. Tjulandin, S.
Journal:
Oncologist

ISSN: 1083-7159 1549-490X

Year of publication: 2012

Volume: 17

Issue: 4

Pages: 469-475

Type: Article

DOI: 10.1634/THEONCOLOGIST.2011-0344 GOOGLE SCHOLAR